{"id":"olanzapine-pamoate-depot","safety":{"commonSideEffects":[{"rate":null,"effect":"Weight gain"},{"rate":null,"effect":"Sedation"},{"rate":null,"effect":"Injection site reactions"},{"rate":null,"effect":"Hyperglycemia"},{"rate":null,"effect":"Hyperlipidemia"},{"rate":null,"effect":"Extrapyramidal symptoms"}]},"_chembl":{"chemblId":"CHEMBL3989694","moleculeType":"Small molecule","molecularWeight":"718.83"},"_dailymed":null,"mechanism":{"_ai_source":"anthropic-haiku","explanation":"Olanzapine antagonizes dopamine D2 receptors and serotonin 5-HT2A receptors, which reduces psychotic symptoms and stabilizes mood. The pamoate salt formulation allows for sustained release from intramuscular injection, providing therapeutic levels for extended periods (typically 2-4 weeks per injection), improving medication adherence in patients with schizophrenia or bipolar disorder.","oneSentence":"Olanzapine pamoate depot is a long-acting intramuscular formulation of olanzapine, an atypical antipsychotic that blocks dopamine D2 and serotonin 5-HT2A receptors in the brain.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:23:56.330Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Schizophrenia (maintenance treatment)"},{"name":"Bipolar I disorder (maintenance treatment)"}]},"trialDetails":[{"nctId":"NCT03367572","phase":"PHASE3","title":"Treatment of Refractory Nausea and Vomiting in Patients With Breast Cancer","status":"COMPLETED","sponsor":"University of Rochester NCORP Research Base","startDate":"2018-04-19","conditions":"Breast Carcinoma","enrollment":1363},{"nctId":"NCT03557931","phase":"PHASE2","title":"A Study to Assess the Safety and Efficacy of ASP4345 as Add-on Treatment for Cognitive Impairment in Subjects With Schizophrenia on Stable Doses of Antipsychotic Medication","status":"COMPLETED","sponsor":"Astellas Pharma Global Development, Inc.","startDate":"2018-07-13","conditions":"Schizophrenia","enrollment":233},{"nctId":"NCT02307396","phase":"PHASE4","title":"Evaluation of the Necessity of Long-term Pharmacological Treatment With Antipsychotics in Schizophrenic Patients","status":"COMPLETED","sponsor":"Technical University of Munich","startDate":"2015-02-01","conditions":"Schizophrenia, Schizophrenia and Disorders With Psychotic Features, Schizoaffective Disorders","enrollment":21},{"nctId":"NCT02529163","phase":"NA","title":"Evaluating the Efficacy of a Late-Life Schizophrenia Integrated Care Pathway to Treat Acute Psychotic Symptoms","status":"UNKNOWN","sponsor":"Centre for Addiction and Mental Health","startDate":"2015-08","conditions":"Schizophrenia, Schizoaffective Disorder","enrollment":24},{"nctId":"NCT00014001","phase":"PHASE4","title":"CATIE- Schizophrenia Trial","status":"COMPLETED","sponsor":"National Institute of Mental Health (NIMH)","startDate":"2000-12","conditions":"Schizophrenia","enrollment":1600},{"nctId":"NCT00320489","phase":"PHASE3","title":"Olanzapine Pamoate Depot Versus Oral Olanzapine on Treatment Outcomes in Outpatients With Schizophrenia","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2006-04","conditions":"Schizophrenia","enrollment":524},{"nctId":"NCT00088465","phase":"PHASE3","title":"Open-Label Study of Intramuscular Olanzapine Depot in Patients With Schizophrenia or Schizoaffective Disorder","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2004-08","conditions":"Schizophrenic Disorders, Schizoaffective Disorder","enrollment":931},{"nctId":"NCT01389908","phase":"NA","title":"A Follow up Study of Intramuscular Olanzapine Depot in Patients With Schizophrenia or Schizoaffective Disorder","status":"UNKNOWN","sponsor":"Shalvata Mental Health Center","startDate":"2011-06","conditions":"Schizophrenia, Schizoaffective Disorders","enrollment":2},{"nctId":"NCT00236457","phase":"PHASE3","title":"A Study Comparing the Efficacy of Long-acting Injectable Risperidone and Olanzapine Tablets in the Treatment of Patients With Schizophrenia or Schizoaffective Disorder","status":"COMPLETED","sponsor":"Johnson & Johnson Pharmaceutical Research & Development, L.L.C.","startDate":"2000-11","conditions":"Schizophrenia, Psychotic Disorders","enrollment":629},{"nctId":"NCT00088491","phase":"PHASE3","title":"Comparison of Intramuscular Olanzapine Depot to Oral Olanzapine and Low-Dose Depot in Patients With Schizophrenia","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2004-06","conditions":"Schizophrenic Disorders","enrollment":1205},{"nctId":"NCT00088478","phase":"PHASE3","title":"Comparison of Intramuscular Olanzapine Depot With Placebo in the Treatment of Patients With Schizophrenia","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2004-06","conditions":"Schizophrenia","enrollment":402},{"nctId":"NCT00094640","phase":"PHASE1","title":"Pharmacokinetic Characterization of Intramuscular Olanzapine Depot","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"","conditions":"Schizophrenia, Schizoaffective Disorder","enrollment":""}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":6,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"olanzapine pamoate depot","genericName":"olanzapine pamoate depot","companyName":"Eli Lilly and Company","companyId":"eli-lilly","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Olanzapine pamoate depot is a long-acting intramuscular formulation of olanzapine, an atypical antipsychotic that blocks dopamine D2 and serotonin 5-HT2A receptors in the brain. Used for Schizophrenia (maintenance treatment), Bipolar I disorder (maintenance treatment).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}